FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer By Ogkologos - July 15, 2026 173 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with... June 9, 2026 Approximately 1 Million of New Maternal Orphans Due to Cancer in... November 28, 2022 Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable... October 5, 2026 Researchers Have Harnessed a Compound from a Common Plant Called Feverfew... August 2, 2019 Load more HOT NEWS Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling... Hable con su médico sobre las opciones de cirugía de mama News digest – naked mole-rats, junk food deals, ovarian cancer drug... Reducing Health Care Disparities Through Cancer Clinical Trials
